Q1 EPS Estimates for Globus Medical Reduced by Roth Capital

Globus Medical, Inc. (NYSE:GMED) – Stock analysts at Roth Capital decreased their Q1 2025 earnings estimates for Globus Medical in a research report issued to clients and investors on Friday, February 21st. Roth Capital analyst J. Wittes now forecasts that the medical device company will post earnings of $0.74 per share for the quarter, down from their previous estimate of $0.75. The consensus estimate for Globus Medical’s current full-year earnings is $3.44 per share. Roth Capital also issued estimates for Globus Medical’s Q2 2025 earnings at $0.82 EPS, Q3 2025 earnings at $0.85 EPS, FY2025 earnings at $3.40 EPS, FY2026 earnings at $4.29 EPS and FY2027 earnings at $4.75 EPS.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Thursday, February 20th. The medical device company reported $0.84 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.10. Globus Medical had a net margin of 4.09% and a return on equity of 10.83%. The firm had revenue of $657.29 million during the quarter, compared to analyst estimates of $646.19 million.

A number of other analysts have also commented on the stock. Morgan Stanley upgraded shares of Globus Medical from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $83.00 to $100.00 in a research note on Monday, December 2nd. Bank of America upgraded shares of Globus Medical from an “underperform” rating to a “neutral” rating and lifted their price target for the stock from $80.00 to $97.00 in a research note on Thursday, January 9th. Truist Financial lifted their price target on shares of Globus Medical from $85.00 to $90.00 and gave the stock a “hold” rating in a research note on Wednesday, December 18th. Piper Sandler boosted their target price on shares of Globus Medical from $80.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, November 6th. Finally, Wells Fargo & Company cut their target price on shares of Globus Medical from $95.00 to $93.00 and set an “overweight” rating for the company in a research report on Friday, February 21st. Three equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $97.82.

Globus Medical Stock Down 0.5 %

Shares of GMED stock opened at $79.65 on Monday. The company has a 50 day moving average price of $86.61 and a 200-day moving average price of $79.25. Globus Medical has a 52 week low of $49.33 and a 52 week high of $94.93. The firm has a market capitalization of $10.85 billion, a PE ratio of 106.20, a P/E/G ratio of 1.61 and a beta of 1.19.

Insider Buying and Selling at Globus Medical

In other Globus Medical news, CFO Keith W. Pfeil sold 14,167 shares of Globus Medical stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $88.29, for a total transaction of $1,250,804.43. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Kelly Huller sold 2,500 shares of Globus Medical stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $87.00, for a total transaction of $217,500.00. The disclosure for this sale can be found here. Insiders own 18.54% of the company’s stock.

Hedge Funds Weigh In On Globus Medical

Several hedge funds have recently modified their holdings of the stock. Polar Asset Management Partners Inc. lifted its holdings in shares of Globus Medical by 73.6% in the fourth quarter. Polar Asset Management Partners Inc. now owns 452,274 shares of the medical device company’s stock worth $37,408,000 after buying an additional 191,700 shares in the last quarter. Burgundy Asset Management Ltd. lifted its holdings in shares of Globus Medical by 1.7% in the fourth quarter. Burgundy Asset Management Ltd. now owns 2,618,108 shares of the medical device company’s stock worth $216,544,000 after buying an additional 43,330 shares in the last quarter. PharVision Advisers LLC purchased a new position in shares of Globus Medical in the fourth quarter worth $339,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Globus Medical by 9.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 319,500 shares of the medical device company’s stock worth $26,426,000 after buying an additional 28,330 shares in the last quarter. Finally, iSAM Funds UK Ltd purchased a new position in shares of Globus Medical in the fourth quarter worth $256,000. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.